[Federal Register Volume 59, Number 97 (Friday, May 20, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-12374]


[[Page Unknown]]

[Federal Register: May 20, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 94M-0128]

 

OrthoLogic Corp.; Premarket Approval of OrthoLogicTM 1000

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
approval of the application by OrthoLogic Corp., Phoenix, AZ, for 
premarket approval, under section 515 of the Federal Food, Drug, and 
Cosmetic Act (the act), of the OrthoLogicTM 1000. FDA's Center for 
Devices and Radiological Health (CDRH) notified the applicant by letter 
on March 4, 1994, of the approval of the application.

DATES: Petitions for administrative review by June 20, 1994.

ADDRESSES: Written requests for copies of the summary of safety and 
effectiveness data and petitions for administrative review to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 
1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Marie A. Schroeder, Center for Devices 
and Radiological Health (HFZ-410), Food and Drug Administration, 1390 
Piccard Dr., Rockville, MD 20850, 301-594-1230.

SUPPLEMENTARY INFORMATION: On November 18, 1991, OrthoLogic Corp., 
Phoenix, AZ 85034, submitted to CDRH an application for premarket 
approval of the OrthoLogicTM 1000. The device is a noninvasive 
osteogenesis therapy system and is indicated for the noninvasive 
treatment of an established nonunion acquired secondary to trauma, 
excluding vertebrae and all flat bones, where the width of the nonunion 
defect is less than one-half the width of the bone to be treated. A 
nonunion is considered to be established when a minimum of 9 months has 
elapsed since injury and the fracture site shows no visibly progressive 
signs of healing in a minimum of 3 months. The OrthoLogicTM 1000 
is a portable, battery-powered, microcontrolled, noninvasive bone 
growth stimulator which produces very low energy combined static and 
dynamic magnetic fields. A Liquid Crystal Display (LCD) is utilized to 
display the status of the device. In accordance with the provisions of 
section 515(f)(2) of the act (21 U.S.C. 360e(f)(2)) as amended by the 
Safe Medical Devices Act of 1990, this PMA was not referred to the 
Orthopedic and Rehabilitation Devices Panel, an FDA advisory panel, for 
review and recommendation because the information in the PMA 
substantially duplicates information previously reviewed by this panel.
     On March 4, 1994, CDRH approved the application by a letter to the 
applicant from the Acting Director of the Office of Device Evaluation, 
CDRH.
    A summary of the safety and effectiveness data on which CDRH based 
its approval is on file in the Dockets Management Branch (address 
above) and is available from that office upon written request. Requests 
should be identified with the name of the device and the docket number 
found in brackets in the heading of this document.

Opportunity for Administrative Review

    Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any 
interested person to petition, under section 515(g) of the act (21 
U.S.C. 360e(g)), for administrative review of CDRH's decision to 
approve this application. A petitioner may request either a formal 
hearing under part 12 (21 CFR part 12) of FDA's administrative 
practices and procedures regulations or a review of the application and 
CDRH's action by an independent advisory committee of experts. A 
petition is to be in the form of a petition for reconsideration under 
Sec. 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form 
of review requested (hearing or independent advisory committee) and 
shall submit with the petition supporting data and information showing 
that there is a genuine and substantial issue of material fact for 
resolution through administrative review. After reviewing the petition, 
FDA will decide whether to grant or deny the petition and will publish 
a notice of its decision in the Federal Register. If FDA grants the 
petition, the notice will state the issue to be reviewed, the form of 
review to be used, the persons who may participate in the review, the 
time and place where the review will occur, and other details.
    Petitioners may, at any time on or before June 20, 1994, file with 
the Dockets Management Branch (address above) two copies of each 
petition and supporting data and information, identified with the name 
of the device and the docket number found in brackets in the heading of 
this document. Received petitions may be seen in the office above 
between 9 a.m. and 4 p.m., Monday through Friday.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under 
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
and redelegated to the Center for Devices and Radiological Health (21 
CFR 5.53).

    Dated: May 11, 1994.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and 
Radiological Health.
[FR Doc. 94-12374 Filed 5-19-94; 8:45 am]
BILLING CODE 4160-01-F